2-chloro-1-(4-(p-tolyl)piperazin-1-yl)ethanone | 63208-61-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-chloro-1-(4-(p-tolyl)piperazin-1-yl)ethanone
• 英文别名: 1-chloroacetyl-4-p-tolyl-piperazine；2-Chloro-1-[4-(4-methylphenyl)piperazin-1-yl]ethanone
• CAS: 63208-61-7
• 化学式: C₁₃H₁₇ClN₂O
• 分子量: 252.744
• InChiKey: ZXUOGVVSGMVROL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-dipropyl-8-(1H-pyrazol-4-yl)-7-(2-trimethylsilanylethoxymethyl)-3,7-dihydro-purine-2,6-dione 、 2-chloro-1-(4-(p-tolyl)piperazin-1-yl)ethanone 在 盐酸 、 potassium carbonate 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 7.0h， 生成 8-{1-[2-oxo-2-(4-p-tolylpiperazin-1-yl)ethyl]-1H-pyrazol-4-yl}-1,3-dipropyl-3,7-dihydropurine-2,6-dione
  参考文献：
  名称：

  A 2B腺苷受体拮抗剂：新型黄嘌呤衍生物的设计，合成和生物学评估

  摘要：

  甲2BA Dor是低亲和力腺苷受体，通过GS功能介导的cAMP的升高和随后的下游信号传导。该受体与肺炎性疾病如COPD和哮喘有关。在文献中已经报道了几种有效的和选择性的A 2B AdoR拮抗剂，但是大多数化合物的药代动力学特性较差。因此，为了鉴定具有改善的药代动力学特性的新颖，有效和选择性的A 2B AdoR拮抗剂，我们首先探索了更受约束的MRS-1754形式（4）。为了改善代谢稳定性，尝试了几种接头修饰，以取代黄嘌呤头基的C8位和末端苯环之间的酰胺接头以及不同的苯基或其他杂芳基。SAR优化导致鉴定了两种新型A 2B AdoR拮抗剂，即8- {1- [5-Oxo-1-（4-三氟甲基-苯基）-吡咯烷-3-基甲基] -1H-吡唑-4-基} -1 ，3-二丙基-黄嘌呤（31）和8-（1- {2-氧代-2- [4-（3-三氟甲基-苯基）-哌嗪-1-基]-乙基} -1H-吡唑-4-基）-1,3-二丙

  DOI：

  10.1016/j.ejmech.2016.11.007
• 作为产物：
  描述：

  1-(4-甲基苯基)哌嗪 、 氯乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-chloro-1-(4-(p-tolyl)piperazin-1-yl)ethanone
  参考文献：
  名称：

  3-Nitrotriazole-based piperazides as potent antitrypanosomal agents

  摘要：

  Novel linear 3-nitro-1H-1,2,4-triazole-based piperazides were synthesized and evaluated as anti-trypanosomal agents. In addition, some bisarylpiperazine-ethanones which were formed as by-products were also screened for antiparasitic activity. Most 3-nitrotriazole-based derivatives were potent and selective against Trypanosoma cruzi parasites, but only one displayed these desired properties against Trypanosoma brucei rhodesiense. Moreover, two 3-nitrotriazole-based chlorophenylpiperazides were moderately and selectively active against Leishmania donovani. Although the bisarylpiperazineethanones were active or moderately active against I cruzi, none of them demonstrated an acceptable selectivity. In general, 3-nitrotriazole-based piperazides were less toxic to host L6 cells than the previously evaluated 3-nitrotriazole-based piperazines and seven of 13 were 1.54- to 31.2-fold more potent antichagasic agents than the reference drug benznidazole. Selected compounds showed good ADMET characteristics. One potent in vitro antichagasic compound (3) was tested in an acute murine model and demonstrated antichagasic activity after a 10-day treatment of 15 mg/kg/day. However, neither compound 3 nor benznidazole showed a statistically significant P value compared to control due to high variability in parasite burden among the untreated animals. Working as prodrugs, 3-nitrotriazole-based piperazides were excellent substrates of trypanosomal type I nitroreductases and constitute a novel class of potentially effective and more affordable antitrypanosomal agents. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.08.042

文献信息

• ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
  申请人：Meng Charles Q.

  公开号：US20140142114A1

  公开（公告）日：2014-05-22

  The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

  本发明涉及以下式（I）的新型驱虫化合物： 其中 Y和Z分别是双环碳环或双环杂环基团，或者Y或Z中的一个是双环碳环或双环杂环基团，另一个是烷基，烯基，炔基，环烷基，苯基，杂环基或杂芳基，以及变量X 1 ，X 2 ，X 3 ，X 4 ，X 5 ，X 6 ，X 7 和X 8 如本文所定义。本发明还提供了包含本发明的驱虫化合物的兽药组合物，以及它们用于治疗和预防动物寄生虫感染的用途。
• [EN] ANTHELMINTIC AGENTS AND THEIR USE<br/>[FR] AGENTS ANTHELMINTHIQUES ET LEUR UTILISATION
  申请人：INTERVET INT BV

  公开号：WO2009077527A1

  公开（公告）日：2009-06-25

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration ofthe compounds and salts to animals in need of the treatments.

  该发明涉及一般用作驱虫剂或作为制备驱虫剂中间体的化合物和盐。该发明还涉及制备这些化合物和盐的工艺、包含这些化合物和盐的药物组合物和工具包、使用这些化合物和盐制作药物以及将这些化合物和盐用于需要治疗的动物的治疗方法。
• New N-Substituted-1,2,4-triazole Derivatives of Pyrrolo[3,4-d]pyridazinone with Significant Anti-Inflammatory Activity—Design, Synthesis and Complementary In Vitro, Computational and Spectroscopic Studies
  作者：Łukasz Szczukowski、Edward Krzyżak、Benita Wiatrak、Paulina Jawień、Aleksandra Marciniak、Aleksandra Kotynia、Piotr Świątek

  DOI：10.3390/ijms222011235

  日期：——

  there is still a current need to search for and develop new, safe and effective anti‑inflammatory agents. As a continuation of our previous work, we designed and synthesized a series of 18 novel N‑substituted-1,2,4-triazole-based derivatives of pyrrolo[3,4‑d]pyridazinone 4a-c-9a-c. The target compounds were afforded via a convenient way of synthesis, with good yields. The executed cell viability assay

  鉴于常用的非甾体抗炎药（NSAIDs）的长期使用往往受到其不良反应的限制，目前仍需要寻找和开发新的、安全有效的抗炎药。作为我们之前工作的延续，我们设计并合成了一系列 18 种新型N-取代-1,2,4-三唑基吡咯并[3,4- d ]哒嗪酮4a - c - 9a - c衍生物。目标化合物通过简便的合成方式得到，收率良好。执行的细胞活力测定显示分子4a - 7a , 9a , 4b- 7b , 4c - 7c不发挥细胞毒性作用，有资格进行进一步研究。根据进行的体外试验，化合物4a - 7a、9a、4b、7b、4c显示出显着的环氧合酶-2 (COX-2) 抑制活性和有希望的 COX-2/COX-1 选择性比。这些发现得到了分子对接研究的支持，该研究表明新衍生物在 COX-2 的活性位点中占据一席之地，与美洛昔康非常相似. 此外，在细胞内进行的体外评估中，标题分子增加了与促炎脂多糖预孵育的细胞的活力，并降低了诱导氧化应激中活性氧和氮物质
• ANTHELMINTIC AGENTS AND THEIR USE
  申请人：Chassaing Christophe Pierre Alain

  公开号：US20110021506A1

  公开（公告）日：2011-01-27

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  本发明涉及化合物和盐，通常用作驱虫剂或作为制备驱虫剂的中间体。本发明还涉及制备这些化合物和盐的方法，包括这些化合物和盐的制药组合物和试剂盒，使用这些化合物和盐制备药物以及将这些化合物和盐用于治疗需要治疗的动物的治疗方法。
• [EN] SELECTIVE HDAC6 INHIBITOR<br/>[FR] INHIBITEUR SÉLECTIF DE HDAC6
  申请人：ROYAL COLLEGE SURGEONS IRELAND

  公开号：WO2022129256A1

  公开（公告）日：2022-06-23

  A compound, which is according to formula (I) or is a pharmaceutically acceptable salt, solvate, ester or pro-drug thereof, for use as a medicament, wherein either (i) NR1R2together forms a 5- or 6- membered heterocyclic ring or (ii) R1and R2are independently selected from H and C1 to C12 alkyl; A is a non-aromatic ring, an aromatic ring or a double bond; X is NR3, S or O, where R3is selected from H and C1 to C12 alkyl; Y is S, NR4, CR4R5, or O, where R4and R5are independently selected from H and C1 to C12 alkyl; and Z is (CR6R7)n where R6and R7are independently selected from H and C1 to C12 alkyl and n is an integer from 1 to 6. The compounds of formula I are particularly useful for the treatment of cancer, neurodegenerative diseases and/or inflammation.

  根据公式(I)或其药学上可接受的盐、溶剂化合物、酯或前药，用作药物的化合物，其中要么(i) NR1R2共同形成5或6元杂环环，要么(ii) R1和R2分别选择自H和C1到C12烷基；A是非芳香环、芳香环或双键；X是NR3、S或O，其中R3选择自H和C1到C12烷基；Y是S、NR4、CR4R5或O，其中R4和R5独立选择自H和C1到C12烷基；Z是（CR6R7）n，其中R6和R7独立选择自H和C1到C12烷基，n是1至6的整数。公式I的化合物特别适用于治疗癌症、神经退行性疾病和/或炎症。